Doripenem is a parenterally-administred antimicrobial of the carbapenem family, with minimum inhibitory concentrations (MIC) of 0.25 ug/mL in Pseudomonas aeruginosa and Escherichia coli. [1] Similar to other b-lactam antibiotics, Doripenem forms stable acyl-enzymes with pencillin-binding proteins, leading to the their inactivation and eventual cell wall rupture.
Doripenem is approved for the treatment of complicated intra-abdominal infections and urinary tract infections. It is active against gram-positive, gram-negative, and anaerobic organisms, and is stable against a wide variety of b-lactamases and renal dehydropeptidases. [2, 3]
Technical information:
| Chemical Formula: | C15H24N4O6S2.H2O | |
| CAS #: | 148016-81-3 | |
| Molecular Weight: | 438.52 | |
| Purity: | > 99% | |
| Appearance: | White | |
| Chemical Name: | 1-Azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid, 3-[[(3S,5S)-5-[[(aminosulfonyl)amino]methyl]-3-pyrrolidinyl]thio]-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-, hydrate | |
| Solubility: | Up to 75 mM in DMSO | |
| Synonyms: | Doripenem, Doribax |
Shipping Condition: The product is shipped in a glass vial at ambient temperature.
Storage condition: For longer shelf life, store solid powder at 4oC desiccated, or store DMSO solution at -20oC.
Reference:
| 1. | Paterson et al., Doripenem. Clin. Infect. Dis. 2009, 49(2), 291-298. Pubmed ID: 19527173 |
| 2. | Matthews et al., Doripenem monohydrate, a broad-spectrum carbapenem antibiotic. Clin. Therapeutics, 2009, 31(1), 42-63. Pubmed ID: 19243706 |
| 3. | Greer et al., Doripenem (Doribax): the newest addition to the carbapenems. Proceedings, Baylor University Medical Center, 2008, 21(3), 337-341. Pubmed ID: 18628935 |
Other Information:
Product Specification (pdf)
MSDS (pdf)
Certificate of Analysis is available upon request.
